Herbal capsule shows promise for heart patients after stent surgery
NCT ID NCT06618495
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a herbal capsule called Xuesaitong (made from Panax notoginseng) can help patients who recently had a heart attack and a stent placed. Sixty adults took the capsule for 4 weeks. Researchers measured changes in platelet genes, proteins, and metabolites to understand how the treatment works and if it is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
60 people
The number who actually took part.
- Started
-
Dec 2024
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * (1) it accords with the diagnostic criteria of western medicine for acute coronary syndrome. (2) within 4 weeks after coronary intervention. (3) 18 years old ≤ age ≤ 80 years old, male or female. (4) voluntarily participate in this clinical trial, give informed consent and sign an informed consent form Exclusion Criteria: * (1) uncontrollable hypertension after drug treatment (systolic blood pressure \> 180mmHg, or diastolic blood pressure \> 110mmHg). (2) increased risk of bleeding: previous history of hemorrhagic stroke; intracranial aneurysms; trauma or major surgery within 1 month (including bypass surgery); diseases currently suffering from active bleeding, etc. (3) patients with history of digestive tract ulcer and massive gastrointestinal bleeding. (4) severe organic heart disease, such as patients with LVEF \< 35% or NYHA/Killip cardiac function grade IV. (5) those with a history of malignant arrhythmias (arrhythmias affected by hemodynamics, requiring drug or electrical cardioversion, or cardiopulmonary resuscitation), congenital heart disease or malignant tumor were considered unable to participate in the trial. (6) severe hepatic and renal insufficiency: glutamic pyruvic transaminase (ALT) or aspartate oxaloacetic transaminase (AST) ≥ 3 × normal upper limit (ULN) or total bilirubin (TBIL) ≥ 2 × ULN; or creatinine clearance (Ccr \< 30ml/min). (7) Women in pregnancy (defined as positive blood pregnancy test) and lactating women. (8) those with a history of blood donation or significant blood loss in the last 3 months (≥ 400ml). (9) people with a previous history of alcoholism (i.e. men drink more than 28 standard units per week and women drink more than 21 standard units per week (1 standard unit contains 14g alcohol, such as 360mL beer or 25mL spirits or 150mL wine with 40% alcohol content); or screen those who drink regularly in the first 6 months (that is, more than 14 standard units per week). (10) those with a history of drug abuse and drug dependence within one year before screening. (11) those who have participated in other clinical trials and taken trial drugs in the past 3 months. (12) people who are allergic or intolerant to aspirin or P2Y12 receptor inhibitors. (13) those who are allergic to the ingredients of the test drugs. (14) other situations in which the researchers think it is not appropriate to participate in this experiment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Beijing, Beijing Municipality, 100091, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tailoring cardiac rehab to each heart: can personalized training speed recovery?
- Can a 20-Minute playlist calm a heart attack Patient's nerves?
- A simple ultrasound test may sharpen heart attack risk predictions
- Could a personal playlist calm nerves during heart surgery?
- Are Europe's heart patients getting the right prevention care? a massive survey aims to find out
- Can a machine support a failing heart without overworking it?